title: First-in-Human Phase 1 Studies in Oncology: The New Challenge for Investigative Sites.
abstract: Phase 1 first-in-human studies with anti-cancer products differ from other phase 1 studies in that they are evaluated in patients rather than healthy volunteers. The rationale design of targeted drugs triggers changes in the design of these studies. Patient populations are more precisely defined and pose a challenge to the efficient inclusion of study patients. Objectives shift from the definition of a maximum tolerated dose to the evaluation of a recommended phase 2 dose. Other challenges related to the efficacy and safety profile of novel targeted anti-cancer drugs call for changes in designing first-in-human studies, such as definitions of biological doses, collection of fresh tumor tissue for surrogate marker analyses, and the management of infusion-related reactions with monoclonal antibodies. Consequently, the conduct of phase 1 clinical trials in oncology requires changes. Corresponding education with particular focus on phase 1 trials and on the complex drug development process needs to be an integrated part of the medical oncology curriculum for physicians and nursing staff. This is a crucial element for institutions to remain or become clinical research sites for phase 1 studies, and to participate in the drug development process of novel anti-cancer compounds in the future.
authors.affiliation: Medpace Inc., Cincinnati, OH, USA and Università degli Studi, Milan, Italy.
authors.forename: Marc
authors.initials: M
authors.lastname: Salzberg
keywords: Challenges; oncology; phase 1; study design
references.citation: Int J Biochem Cell Biol. 2007;39(7-8):1375-87
references.pmid: 17543572
references.citation: Br J Cancer. 2009 May 5;100(9):1373-8
references.pmid: 19401696
references.citation: Breast J. 2012 Jan-Feb;18(1):41-51
references.pmid: 22098334
references.citation: J Clin Oncol. 2011 Oct 1;29(28):3783-90
references.pmid: 21900113
references.citation: Clin Cancer Res. 2010 Mar 15;16(6):1745-55
references.pmid: 20215558
references.citation: J Natl Cancer Inst. 1997 Aug 6;89(15):1138-47
references.pmid: 9262252
references.citation: Ann Oncol. 2004 Sep;15(9):1305-9
references.pmid: 15319234
references.citation: J Clin Oncol. 2008 Apr 20;26(12):1926-31
references.pmid: 18421046
references.citation: Expert Opin Biol Ther. 2011 Jul;11(7):937-49
references.pmid: 21557708